RxDoctor Payments Data

Druhan Howell, MD

Allergy · Mobile, ALNPI 1790877892

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $151,880 of the $200,891 with a category attached, or 75.6%. AstraZeneca accounts for 60.1% of it on its own, with 48 other manufacturers making up the rest. 2025 is the largest year on record at $50,497, more than ten times the $4,253 reported in 2019.

$200,891in general payments, 2019–2025

Across 1,149 payments — averaging $174.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$121K
  • Organon$28K
  • Amgen$20K
  • Dermavant Sciences, Inc.$16K
  • Pfizer$4K
  • GSK$2K
  • plus $11K from 43 others

What the payments were for

  • Consulting fees$15,3708%
  • Speaking & faculty fees$151,88076%
  • Travel & lodging$9,6115%
  • Food & beverage$23,62912%
  • Education$4010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in Alabamato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$14,036
Medicare patients
43
Services billed
809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5015$216,278
NucalaMepolizumab12$154,088
XolairOmalizumab29$90,233
Dupixent PenDupilumab17$64,055
DuleraMometasone/Formoterol14$6,427
Mometasone Furoate32$4,766
Epinephrine12$2,280
Ipratropium Bromide29$1,214
Levocetirizine Dihydrochloride33$917
Fluticasone Propionate30$468
Montelukast Sodium30$408
Azelastine Hcl13$347
Famotidine13$329
Albuterol Sulfate HfaAlbuterol Sulfate12$293
Hydroxyzine Hcl15$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru$1,540$216,27815 claims
GSKNucala$2,423$154,08812 claims
MerckDulera$223$6,42714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Alabamaon file to place this against a meaningful peer group, so we don't.

Other allergy in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →